ReviewBMC medicine2012
Is inhibition of kinase activity the only therapeutic strategy for LRRK2-associated Parkinson's disease?
Review in BMC medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Roc, the G-domain of the Parkinson's disease-associated protein LRRK2.Trends in biochemical sciences · 2022Review
- Article
- LRRK2 and Proteostasis in Parkinson's Disease.International journal of molecular sciences · 2022Review
- Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease.Acta pharmaceutica Sinica. B · 2021Review
- Generation of fourteen isogenic cell lines for Parkinson's disease-associated leucine-rich repeat kinase (LRRK2).Stem cell research · 2021Article
- Article
- Genetic Defects and Pro-inflammatory Cytokines in Parkinson's Disease.Frontiers in neurology · 2021Review
- Allosteric inhibition of LRRK2, where are we now.Biochemical Society transactions · 2020Review
- Lrrk2 modulation of Wnt signaling during zebrafish development.Journal of neuroscience research · 2020Article
- LRRK2 in Parkinson disease: challenges of clinical trials.Nature reviews. Neurology · 2020Review
- LRRK2 regulation of immune-pathways and inflammatory disease.Biochemical Society transactions · 2019Review
- Synthesis and Preliminary Evaluation of [ChemMedChem · 2019Article
- Differences in Stability, Activity and Mutation Effects Between Human and Mouse Leucine-Rich Repeat Kinase 2.Neurochemical research · 2019Article
- Roco Proteins and the Parkinson's Disease-Associated LRRK2.International journal of molecular sciences · 2018Review
- Parkinson's disease: convergence on synaptic homeostasis.The EMBO journal · 2018Review
- LRRK2 promotes the activation of NLRC4 inflammasome duringThe Journal of experimental medicine · 2017Article
- Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission.CNS neuroscience & therapeutics · 2017Article
- Review
- The function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research.The Biochemical journal · 2016Review
- Cellular processes associated with LRRK2 function and dysfunction.The FEBS journal · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are a common cause of familial Parkinson's disease (PD). Variation around the LRRK2 locus also contributes to the risk of sporadic PD. The LRRK2 protein contains a central catalytic region, and pathogenic mutations cluster in the Ras of complex protein C terminus of Ras of complex protein (mutations N1437H, R1441G/C and Y1699C) and kinase (G2019S and I2020T) domains. Much attention has been focused on the kinase domain, because kinase-dead versions of mutant LRRK2 are less toxic than kinase-active versions of the same proteins. Furthermore, kinase inhibitors may be able to mimic this effect in mouse models, although the currently tested inhibitors are not completely specific. In this review, we discuss the recent progress in the development of specific LRRK2 kinase inhibitors. We also discuss non-kinase-based therapeutic strategies for LRRK2-associated PD as it is possible that different approaches may be needed for different mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.